Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer

BMC Research Notes

William E Grizzle⁴  Martin R Johnson²  Suzanne Byan-Parker⁴  Mark R Steciuk⁴  Qinghua He¹  Adam D Steg³  Jessica M Grunda⁵ 

[1] Department of Chemical Engineering, Tuskegee University, Tuskegee, AL, 36088, USA;Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA;Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA;Department of Pathology, University of Alabama at Birmingham, Zeigler Research Building, 703 South 19th Street, ZRB 408, Birmingham, AL, 35294, USA;Department of Medicine, Division of Endocrinology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA

关键词: Cell migration;    Cell cycle;    Estrogen signaling;    Race;    Gene expression;    Breast cancer;   

Others  :  1166403
DOI  :  10.1186/1756-0500-5-248

 received in 2011-09-01, accepted in 2012-04-25,  发布年份 2012

【 摘 要 】

Background

Recent studies suggest that the poorer breast cancer outcome observed in African-American women (AAW) may, in part, result from underlying molecular factors. The purpose of this study was to investigate gene expression differences between Caucasian-American women (CAW) and AAW that may contribute to this poorer prognosis.

Methods

The expression of 84 genes involved in breast carcinoma prognosis, response to therapy, estrogen signaling, and tumor aggressiveness was assessed in age- and stage-matched CAW and AAW paraffin-embedded breast cancer specimens. The Wilcoxon–Mann–Whitney Test was used to identify genes with a significant difference in expression between CAW and AAW. To determine if the differentially expressed genes could segregate between the CAW and AAW, we performed semi-supervised principal component analysis (SSPCA).

Results

Twenty genes were differentially expressed between AAW and CAW. SSPCA incorporating these 20 genes segregated AAW and CAW into two distinct groups. AAW were significantly (p < 0.05) more likely to display aberrations in G₁/S cell-cycle regulatory genes, decreased expression of cell-adhesion genes, and low to no expression of ESR1, PGR, ERBB2 and estrogen pathway targets.

Conclusions

The gene expression differences identified between AAW and CAW may contribute to more aggressive disease, resistance to therapy, enhanced metastatic potential and poor clinical outcome. These findings support the hypothesis that breast cancer specimens collected from AAW display distinct gene expression differences compared to similar tissues obtained from CAW. Additional population-based studies are necessary to determine if these gene expression variations contribute to the highly aggressive and treatment-resistant breast cancer phenotype frequently observed in AAW.

【 授权许可】

   
2012 Grunda et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Society AC: Breast cancer facts and figures: 2009–2010. American Cancer Society, Inc., Atlanta; 2009.
• [2]Society AC: Cancer Fact and Figures for African Americans 2011–2012. American Cancer Society, Atlanta; 2011.
• [3]Newman LA: Breast cancer in African-American women. Oncologist 2005, 10(1):1-14.
• [4]Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C, Sobhan M, et al.: Histological characteristics of breast carcinoma in blacks and whites. Canc Epidemiol Biomarkers Prev 1994, 3(2):127-135.
• [5]Fedewa SA, Edge SB, Stewart AK, Halpern MT, Marlow NM, Ward EM: Race and ethnicity are associated with delays in breast cancer treatment (2003–2006). J Health Care Poor Underserved 2011, 22(1):128-141.
• [6]Fedewa SA, Ward EM, Stewart AK, Edge SB: Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 2010, 28(27):4135-4141.
• [7]Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL: The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2011, 117(1):180-189.
• [8]Gullate M: The influence of spirituality and religiosity on breast cancer screening delay in African American women: application of the Theory of Reasoned Action and Planned Behavior (TRA/TPB). ABNF J 2006, 17(2):89-94.
• [9]Wang J, John EM, Horn-Ross PL, Ingles SA: Dietary fat, cooking fat, and breast cancer risk in a multiethnic population. Nutr Cancer 2008, 60(4):492-504.
• [10]Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA: Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 2006, 24(9):1342-1349.
• [11]Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D, Colditz GA: African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer 2002, 94(11):2844-2854.
• [12]Jatoi I, Becher H, Leake CR: Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U.S. Department of Defense Healthcare system. Cancer 2003, 98(5):894-899.
• [13]Wojcik BE, Spinks MK, Optenberg SA: Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer 1998, 82(7):1310-1318.
• [14]Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009, 101(14):984-992.
• [15]Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
• [16]Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
• [17]Amend K, Hicks D, Ambrosone CB: Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 2006, 66(17):8327-8330.
• [18]Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007, 14(10):2994-3003.
• [19]Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 1991, 68(2):331-334.
• [20]Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW: Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004, 100(12):2533-2542.
• [21]Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005, 46(6):685-693.
• [22]Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW: Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113(2):357-370.
• [23]Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW: BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009, 115(10):2222-2233.
• [24]Field LA, Love B, Deyarmin B, Hooke JA: Shriver CD. Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer, Ellsworth RE; 2011.
• [25]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010, 134(6):907-922.
• [26]Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME: Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009, 133(4):611-612.
• [27]Steg A, Vickers SM, Eloubeidi M, Wang W, Eltoum IA, Grizzle WE, Saif MW, Lobuglio AF, Frost AR, Johnson MR: Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. Diagn Mol Pathol 2007, 16(4):229-237.
• [28]Blanquicett C, Johnson MR, Heslin M, Diasio RB: Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 2002, 303(2):209-214.
• [29]Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, et al.: Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 2006, 8(1):76-83.
• [30]Fisher RA: Statistical Methods for Research Workers. Oliver and Boyd, ; 1954.
• [31]Hallander M, Wolfe D: Nonparametric Statistical Methods. 1999, :. (2nd)
• [32]Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004, 2(4):E108.
• [33]Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, et al.: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360(5):470-480.
• [34]Massey F: The Kolmogorov-Smirnov test for goodness of fit. J Am Stat Assoc 1951, 46(253):68-78.
• [35]Johnson R, Wichern D: Applied Multivariate Statistical Analysis. Prentice-Hall, Inc, ; 1982.
• [36]Farragher SM, Tanney A, Kennedy RD, Paul Harkin D: RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 2008, 130(3):435-445.
• [37]Klopfleisch R, Weiss AT, Gruber AD: Excavation of a buried treasure–DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol Histopathol 2011, 26(6):797-810.
• [38]Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, et al.: Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol 2006, 80(3):261-274.
• [39]Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997, 3(2):222-225.
• [40]Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, et al.: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997, 3(2):227-230.
• [41]Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C: Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med 1998, 4(12):807-822.
• [42]Han S, Ahn SH, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY: P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res Treat 2001, 70(3):205-212.
• [43]Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001, 67(1):61-70.
• [44]Steeg PS, Zhou Q: Cyclins and breast cancer. Breast Cancer Res Treat 1998, 52(1–3):17-28.
• [45]Satyanarayana A, Kaldis P: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28(33):2925-2939.
• [46]Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996, 73(6):728-734.
• [47]Christov K, Ikui A, Shilkaitis A, Green A, Yao R, You M, Grubbs C, Steele V, Lubet R, Weinstein IB: Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat 2003, 77(3):253-264.
• [48]Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G: G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat 1999, 56(2):105-112.
• [49]Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 1998, 79(1):71-75.
• [50]Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, et al.: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005, 97(6):439-448.
• [51]Joslyn SA: Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002, 73(1):45-59.
• [52]Elledge RM, Clark GM, Chamness GC, Osborne CK: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994, 86(9):705-712.
• [53]Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001, 92(1):37-45.
• [54]Callahan R, Hurvitz S: Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 2011, 23(1):37-43.
• [55]Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, et al.: Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011, 128(1):147-154.
• [56]Burris HA: Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011, 11(6):807-819.
• [57]Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I: Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006, 13(4):1109-1120.
• [58]Wilson BJ, Giguere V: Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 2008, 7:49. BioMed Central Full Text
• [59]Kallel-Bayoudh I, Hassen HB, Khabir A, Boujelbene N, Daoud J, Frikha M, Sallemi-Boudawara T, Aifa S, Rebai A: Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol 2010, 28(Suppl 1):S55-S61.
• [60]Spyratos F, Andrieu C, Vidaud D, Briffod M, Vidaud M, Lidereau R, Bieche I: CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Int J Biol Markers 2000, 15(3):210-214.
• [61]Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes LF, Firestone GL: Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop. Mol Biol Cell 2010, 21(7):1166-1177.
• [62]Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG: Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Canc Res 2005, 65(24):11259-11264.
• [63]Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO: Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005, 18(10):1295-1304.
• [64]Wei X, Xu H, Kufe D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006, 21(2):295-305.
• [65]Napieralski R, Brunner N, Mengele K, Schmitt M: Emerging biomarkers in breast cancer care. Biomark Med 2010, 4(4):505-522.
• [66]Minisini AM, Fabbro D, Di Loreto C, Pestrin M, Russo S, Cardellino GG, Andreetta C, Damante G, Puglisi F: Markers of the uPA system and common prognostic factors in breast cancer. Am J Clin Pathol 2007, 128(1):112-117.
• [67]Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, Eren M, Vaughan DE: Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circ Res 2004, 95(3):269-275.
• [68]Cimino D, Fuso L, Sfiligoi C, Biglia N, Ponzone R, Maggiorotto F, Russo G, Cicatiello L, Weisz A, Taverna D, et al.: Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Canc J Int du cancer 2008, 123(6):1327-1338.
• [69]Yamamura J, Miyoshi Y, Tamaki Y, Taguchi T, Iwao K, Monden M, Kato K, Noguchi S: mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Cancer Sci 2004, 95(11):887-892.
• [70]Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Canc Res 2002, 62(5):1289-1295.
• [71]Michels KM, Lee WH, Seltzer A, Saavedra JM, Bondy CA: Up-regulation of pituitary [125I]insulin-like growth factor-I (IGF-I) binding and IGF binding protein-2 and IGF-I gene expression by estrogen. Endocrinology 1993, 132(1):23-29.
• [72]Rooman RP, De Beeck LO, Martin M, Van Doorn J, Mohan S, Du Caju MV: IGF-I, IGF-II, ‘free’ IGF-I and IGF-binding proteins-2 to −6 during high-dose oestrogen treatment in constitutionally tall girls. Eur J Endocrinol 2002, 146(6):823-829.
• [73]Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB: Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocrine-related cancer 2006, 13(2):617-628.
• [74]Graham JD, Roman SD, McGowan E, Sutherland RL, Clarke CL: Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem 1995, 270(51):30693-30700.
• [75]Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J 1990, 9(5):1603-1614.
• [76]Saucedo R, Basurto L, Zarate A, Martinez C, Hernandez M, Galvan R: Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women. Gynecol Obstet Invest 2007, 64(2):61-64.
• [77]Adams DJ, Hajj H, Edwards DP, Bjercke RJ, McGuire WL: Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. Can Res 1983, 43(9):4297-4301.
• [78]Andersen J, Skovbon H, Poulsen HS: Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy. Eur J Cancer Clin Oncol 1989, 25(4):641-643.
• [79]Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL: Estrogen-induced 24 K protein in MCF-7 breast cancer cells is localized in granules. Breast Canc Res Treat 1984, 4(4):261-268.
• [80]Kroll J, Briand P: Estrogen-dependent release of serum proteins from MCF-7 breast carcinoma cells in vitro. Anticancer Res 1988, 8(1):89-91.
• [81]Massot O, Baskevitch PP, Capony F, Garcia M, Rochefort H: Estradiol increases the production of alpha 1-antichymotrypsin in MCF7 and T47D human breast cancer cell lines. Mol Cell Endocrinol 1985, 42(3):207-214.
• [82]Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, et al.: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Brit J Canc 2010, 103(5):668-675.
• [83]Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y: Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Canc Res 2008, 10(2):R35. BioMed Central Full Text
• [84]Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996, 69(2):92-99.
• [85]Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 2006, 24(11):1656-1664.
• [86]Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, Mah V, Bose S, Chia D, Chang HR, et al.: Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 2010, 41(12):1794-1801.
• [87]Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A: Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 2000, 88(9):2061-2071.
• [88]Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkila R, Kvaloy JT, Gilje B, Smaaland R, Nordgard O: Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 2010, 10(5):378-384.
• [89]van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J: The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 2007, 51(3):322-335.
• [90]Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Canc Res Treat 1983, 3(2):157-163.
• [91]Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM: Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Canc Res: an official Journal of the American Association for Cancer Research 2007, 13(11):3164-3173.
• [92]Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 2006, 449(1):24-30.
• [93]Anderson JM, Van Itallie CM: Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009, 1(2):a002584.
• [94]Gupta IR, Ryan AK: Claudins: unlocking the code to tight junction function during embryogenesis and in disease. Clin Genet 2010, 77(4):314-325.
• [95]Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65(21):9603-9606.
• [96]Blackman B, Russell T, Nordeen SK, Medina D, Neville MC: Claudin 7 expression and localization in the normal murine mammary gland and murine mammary tumors. Breast Cancer Res 2005, 7(2):R248-R255. BioMed Central Full Text
• [97]Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22(13):2021-2033.
• [98]Sauer T, Pedersen MK, Ebeltoft K, Naess O: Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 2005, 16(4):193-198.
• [99]Lahoz A, Hall A: DLC1: a significant GAP in the cancer genome. Genes Dev 2008, 22(13):1724-1730.
• [100]Sekimata M, Kabuyama Y, Emori Y, Homma Y: Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J Biol Chem 1999, 274(25):17757-17762.
• [101]Zhou X, Thorgeirsson SS, Popescu NC: Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 2004, 23(6):1308-1313.
• [102]Durkin ME, Yuan BZ, Thorgeirsson SS, Popescu NC: Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene 2002, 288(1–2):119-127.
• [103]Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC: DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003, 22(3):445-450.
• [104]Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998, 58(10):2196-2199.
• [105]Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S: Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol 2003, 129(6):349-354.
• [106]Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye MA: Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res 2008, 68(21):8743-8751.